Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics (original) (raw)

• Nichols DE. Psychedelics. Pharm Rev. 2016;68:264.
  PubMed PubMed Central CAS Google Scholar
• Glennon RA. Classical hallucinogens: an introductory overview. NIDA Res Monogr. 1994;146:4–32.
• Hanks JB, González-Maeso J. Hallucinogens: circuits, behavior, and translational models. neuropathology of drug addictions and substance misuse. Volume 2: stimulants, club and dissociative drugs, hallucinogens, steroids, inhalants and international aspects. Elsevier; 2016. p. 813–20.
• Hanks JB, González-Maeso J. Molecular and cellular basis of hallucinogen action. neuropathology of drug addictions and substance misuse. Volume 2: stimulants, club and dissociative drugs, hallucinogens, steroids, inhalants and international aspects. Elsevier; 2016. p. 803–12.
• López-Giménez JF, González-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45–73.
  PubMed PubMed Central Google Scholar
• Hofmann A. LSD: my problem child. New York: McGraw-Hil; 1980.
• González-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 2009;32:225–32.
  PubMed Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen Margreet FI, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia like psychosis in humans via serotonin-2 agonist action. Neuro Rep. 1998;19:2897–3902.
  Google Scholar
• Young BG. A phenomenological comparison of LSD and schizophrenic states. Br J Psychiatry. 1974;124:64–74.
  PubMed CAS Google Scholar
• Hermle L, Ftinfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry. 1992;32:976–91.
• Hoch PH, Cattell JP, Pennes HH. Effects of mescaline and lysergic acid (d-LSD-25).
• Anastasopoulos G, Photiades H. Effects of LSD-25 on relatives of schizophrenic patients. Ment Sci. 1962;108:95–8.
• Reynolds GP, Rossor MN, Iversen LL. Preliminary studies of human cortical 5-HT receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl. 1983;18:273–7.
  PubMed CAS Google Scholar
• Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry. 2022;28:44–58.
  PubMed Google Scholar
• Colpaert FC. Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov. 2003;2:315–20.
  PubMed CAS Google Scholar
• Busch AK, Johnson WC. L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst. 1950;11:241–3.
• Kupferschmidt K. High hopes. Science (1979). 2014;345:18–23.
  CAS Google Scholar
• Clark P, Jay M. Mescaline: A Global History of the First Psychedelic, Social History of Medicine, 2020;33:1032–3.
• Nutt JD, King AL, Nichols ED. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Neurosci Rev. 2013;14:577–85.
  CAS Google Scholar
• Oram M. Efficacy and enlightenment: LSD psychotherapy and the drug amendments of 1962. J Hist Med Allied Sci. 2014;69:221–50.
  PubMed Google Scholar
• de Osório FL, Sanches RF, Macedo LR, dos Santos RG, Maia-De-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37:13–20.
  PubMed Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatning cancer: a randomized double-blind trial. Psychopharmacology. 2016;30:1181–97.
  CAS Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619–27.
  PubMed Google Scholar
• Nichols DE. Chemistry and structure–activity relationships of psychedelics. Curr Top Behav Neurosci. 2017;36:1–43.
  Google Scholar
• Nichols DE, Nichols CD, Hendricks PS. Proposed consensus statement on defining psychedelic drugs. Psychedelic Medicine. 2022;1:12–13. https://doi.org/10.1089/PSYMED.2022.0008.
• Nichols DE. Entactogens: how the name for a novel class of psychoactive agents originated. Front Psychiatry. 2022;13:863088.
  PubMed PubMed Central Google Scholar
• Dai R, Larkin TE, Huang Z, Tarnal V, Picton P, Vlisides PE, et al. Classical and non-classical psychedelic drugs induce common network changes in human cortex. Neuroimage. 2023;273:120097.
  PubMed Google Scholar
• Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharm Rev. 2021;73:202–77.
  PubMed CAS Google Scholar
• Halberstadt AL, Geyer MA.Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Neuropharmacology. 2011;61:364–81. https://doi.org/10.1016/j.neuropharm.2011.01.017.
  Article PubMed PubMed Central CAS Google Scholar
• Chadeayne AR, Manke DR, Pham DNK, Reid BG, Golen JA. Active metabolite of aeruginascin (4-Hydroxy-N,N,N-trimethyltryptamine): synthesis, structure, and serotonergic binding affinity. ACS Omega. 2020;5:16940–3.
  PubMed PubMed Central CAS Google Scholar
• Roth BL, Lopez E, Patel S, Ley W, Kroeze K. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist. 2000;6:252–62.
• Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J Med Chem. 2002;45:4344–9.
  PubMed CAS Google Scholar
• Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther. 1990;255:843–57.
  PubMed CAS Google Scholar
• Mckenna DJ, Peroutka SJ. Differentiation of 5=hydroxytryptamine, receptor subtypes using 125l-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin. J Neurosci. 1989;9:3482–90. vol
  PubMed PubMed Central CAS Google Scholar
• Glennon RA, Young R, Benington F, Morin RD. Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane. J Med Chem. 1982;25:1163–8.
  PubMed CAS Google Scholar
• Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505–11.
  PubMed CAS Google Scholar
• Hanks JB, González-Maeso J. Animal models of serotonergic psychedelics. ACS Chem Neurosci. 2013;4:33–42.
  PubMed CAS Google Scholar
• Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544–53.
  PubMed CAS Google Scholar
• Mack Whitaker-Azmitia P. The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology. 1999;21:2S–8S.
• McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. Pharm Ther. 2015;150:129–42.
  CAS Google Scholar
• Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther. 2008;31:187–99.
• Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res. 2008;195:198–213.
  PubMed CAS Google Scholar
• Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology. 2020;177:108155.
  PubMed CAS Google Scholar
• Sarkar P, Mozumder S, Bej A, Mukherjee S, Sengupta J, Chattopadhyay A. Structure, dynamics and lipid interactions of serotonin receptors: excitements and challenges. Biophys Rev 2021;13;101–22.
• Weis WI, Kobilka BK. The molecular basis of G protein–coupled receptor activation. Annu Rev Biochem. 2018;87:897.
  PubMed PubMed Central CAS Google Scholar
• Pincas H, González-Maeso J, Ruf-Zamojski F, Sealfon SC. G protein-coupled receptors. In: Belfiore, A., LeRoith, D. editors Principles of Endocrinology and Hormone Action. Endocrinology. Springer, Cham; 2018:85–120.
• Davies MN, Secker A, Freitas AA, Mendao M, Timmis J, Flower DR. On the hierarchical classification of G protein-coupled receptors. Bioinformatics. 2007;23:3113–8.
  PubMed CAS Google Scholar
• Erlandson SC, McMahon C, Kruse AC. Structural basis for G protein–coupled receptor signaling. Annu Rev Biophys. 2018;47:1–18. https://doi.org/10.1146/Annurev-Biophys-070317-032931.
• Sato J, Makita N, Iiri T. Inverse agonism: the classic concept of GPCRs revisited. Endocr J. 2016;63:507–14.
  PubMed CAS Google Scholar
• Hodavance SY, Gareri C, Torok RD, Rockman HA. G protein-coupled receptor biased agonism. J Cardiovasc Pharm. 2016;67:193–202.
  CAS Google Scholar
• Oldham WM, Hamm HE. Structural basis of function in heterotrimeric G proteins. Q Rev Biophys. 2006;39:117–66.
  PubMed CAS Google Scholar
• Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 2007;9:60–71.
  Google Scholar
• Logothetis DE, Kurachi Y, Galper J, Neer EJ, Clapham DE. The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart. Nature. 1987;325:321–6.
  PubMed CAS Google Scholar
• Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, et al. International union of basic and clinical pharmacology. Cx. Classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharm Rev. 2021;73:310–520.
  PubMed PubMed Central CAS Google Scholar
• Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharm Ther. 2001;92:179–212.
  CAS Google Scholar
• Celada P, Puig MV, Artigas F, Wong-Lin K, Gruber A. Serotonin modulation of cortical neurons and networks. Front. Integr. Neurosci. 2013;7:25.
• Matos FF, Urban C, Yocca FD. Serotonin (5-HT) release in the dorsal raphe and ventral hippocampus: raphe control of somatodendritic and terminal 5-HT release. J Neural Transm. 1996;103:173–90.
  PubMed CAS Google Scholar
• López-Giménez JF, Mengod G, Palacios JM, Teresa Vilaró M. Human striosomes are enriched in 5-HT2A receptors: autoradiographical visualization with [3H]MDL100,907, [125I](±)DOI and [3H]ketanserin. Eur J Neurosci. 1999;11:3761–5.
  PubMed Google Scholar
• Schreiber R, Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation. Neurobiol Learn Mem. 2014;110:72–80.
  PubMed CAS Google Scholar
• Gardier AM, Malagié I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharm. 1996;10:16–27.
  CAS Google Scholar
• Artigas F, Nutt D, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull. 2002 Summer;36 Suppl 2:123–32.
• Moutkine I, Collins EL, Béchade C, Maroteaux L. Evolutionary considerations on 5-HT2 receptors. Pharm Res. 2019;140:14–20.
  CAS Google Scholar
• Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol. 2010;38:837–48.
  PubMed CAS Google Scholar
• Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharm. 1984;106:539–46.
  CAS Google Scholar
• Adlersberg M, Arango V, Hsiung S-C, Mann JJ, Underwood MD, Liu K-P, et al. In vitro autoradiography of serotonin 5-HT 2A/2C receptor-activated G protein: guanosine-5-(-[35 S]Thio)triphosphate binding in rat brain. J Neurosci Res. 2000;61:674–85.
  PubMed CAS Google Scholar
• Wold EA, Wild CT, Cunningham KA, Zhou J. Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development. Curr Top Med Chem. 2019;19:1381.
  PubMed PubMed Central CAS Google Scholar
• Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995;374:542–46.
  PubMed CAS Google Scholar
• López-Giménez JF, Mengod G, Palacios JM, Vilaró MT. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn-Schmiedeberg’s Arch Pharmacol. 1997;356:446–54.
  Google Scholar
• López-Giménez JF, Vilaró MT, Palacios JM, Mengod G. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology. 1998;37:1147–58.
  PubMed Google Scholar
• López-Giménez JF, Tecott LH, Palacios JM, Mengod G, Vilaró MT. Serotonin 2C receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res. 2002;67:69–85.
  PubMed Google Scholar
• Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355.
  PubMed PubMed Central CAS Google Scholar
• Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206–27. 12. 2012;17
  PubMed CAS Google Scholar
• Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393–406. https://doi.org/10.1146/Annurev-Med-050911-161504.
• Amato D. Serotonin in antipsychotic drugs action. Behav Brain Res. 2015;277:125–35.
  PubMed CAS Google Scholar
• González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452:93–97.
  PubMed PubMed Central Google Scholar
• Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013;23:852.
  PubMed CAS Google Scholar
• García-Bea A, Miranda-Azpiazu P, Muguruza C, Marmolejo-Martinez-Artesero S, Diez-Alarcia R, Gabilondo AM, et al. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: selective biased agonism via Gαi1-proteins. Eur Neuropsychopharmacol. 2019;29:1453–63.
  PubMed Google Scholar
• Kurita M, Holloway T, GarcÃ- A-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15:1245–54.
  PubMed PubMed Central CAS Google Scholar
• Ibi D, de La Fuente Revenga M, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al. Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nat Neurosci. 2017;20:1247–59. 9. 2017;20
  PubMed PubMed Central CAS Google Scholar
• De La M, Revenga F, Ibi D, Saunders JM, Cuddy T, Ijaz MK, et al. HDAC2-dependent antipsychotic-like effects of chronic treatment with the HDAC inhibitor SAHA in mice HHS public access. Neuroscience. 2018;388:102–17.
  Google Scholar
• Sealfon SC, Chi L, Ebersolell BJ, Rodier V, Zhang D, Ballesterostz JA, et al. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor*. J Biol Chem. 1995;270:16683–8. vol
  PubMed CAS Google Scholar
• Ebersole BJ, Visiers I, Weinstein H, Sealfon SC. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol Pharmacol. 2003;63:36–43.
• Almaula N, Ebersole BJ, Zhang D, Weinstein H, Sealfon SC. Mapping the binding site pocket of the serotonin 5-hydroxytryptamine 2A receptor Ser 3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin*. J Biol Chem. 1996;271:14672–5.
• Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289:739–45.
  PubMed CAS Google Scholar
• Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, et al. Structural basis for molecular recognition at serotonin receptors. Science. 2013;340:610.
  PubMed PubMed Central CAS Google Scholar
• Liu W, Wacker D, Gati C, Han GW, James D, Wang D, et al. Serial femtosecond crystallography of G protein-coupled receptors. Science. 2013;342:1521–4.
  PubMed PubMed Central CAS Google Scholar
• Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, et al. Crystal structure of an LSD-bound human serotonin receptor. Cell. 2017;168:377–389.e12.
  PubMed PubMed Central CAS Google Scholar
• Kimura KT, Asada H, Inoue A, Marie F, Kadji N, Im D, et al. Structures of the 5-HT 2A receptor in complex with the antipsychotics risperidone and zotepine. Nature. 2019;26:121–8.
  CAS Google Scholar
• Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1995;25:366–428.
  CAS Google Scholar
• Wu Y, Zeng L, Zhao S. Ligands of adrenergic receptors: a structural point of view. Biomolecules. 2021. 2021. https://doi.org/10.3390/biom11070936.
• Wacker D, Wang C, Katritch V, Han GW, Huang X-P, Vardy E, et al. Structural features for functional selectivity at serotonin receptors. Science. 2013;340:615–9.
• Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell. 2020;182:1574–1588.e19.
  PubMed PubMed Central CAS Google Scholar
• Moreno JL, Miranda-Azpiazu P, García-Bea A, Younkin J, Cui M, Kozlenkov A, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal. 2016;9:ra5.
  PubMed PubMed Central Google Scholar
• Urban JD, Clarke WP, Von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320:1–13.
  PubMed CAS Google Scholar
• Gonzalez-Maeso J, Sealfon S. Agonist-trafficking and hallucinogens. Curr Med Chem. 2009;16:1017–27.
  PubMed CAS Google Scholar
• Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science. 2022;375:403–11.
• González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439–52.
  PubMed Google Scholar
• Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharm Sci. 2008;29:445–53.
  PubMed CAS Google Scholar
• Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33:10544–51.
  PubMed PubMed Central CAS Google Scholar
• González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci. 2003;23:8836–43.
  PubMed PubMed Central Google Scholar
• Karaki S, Becamel C, Murat S, Cour CML, Millan MJ, Prezeau L, et al. Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Mol Cell Proteom. 2014;13:1273.
  CAS Google Scholar
• Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. 1999;21:16–23.
  Google Scholar
• Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA. 1998;95:735–40.
  PubMed PubMed Central CAS Google Scholar
• Gewirtz JC, Marek GJ. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology. 2000;23:569–76.
  PubMed CAS Google Scholar
• de la Fuente Revenga M, Shin JM, Vohra HZ, Hideshima KS, Schneck M, Poklis JL, et al. Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo. Sci Rep. 2019;9:14247.
  PubMed PubMed Central Google Scholar
• Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett. 2011;493:76.
  PubMed PubMed Central CAS Google Scholar
• Benvenga MJ, Chaney SF, Baez M, Britton TC, Hornback WJ, Monn JA, et al. Metabotropic glutamate2 receptors play a key role in modulating head twitches induced by a serotonergic hallucinogen in mice. Front Pharm. 2018;9:208.
  Google Scholar
• Saha S, González-Maeso J. The crosstalk between 5-HT2AR and mGluR2 in schizophrenia. Neuropharmacology. 2023;230:109489.
  PubMed CAS Google Scholar
• Shah UH, González-Maeso J. Serotonin and glutamate interactions in preclinical schizophrenia models. ACS Chem Neurosci. 2019;10:3068–77.
  PubMed CAS Google Scholar
• Schmid CL, Raehal KM, Bohn LM, Lefkowitz RJ. Agonist-directed signaling of the serotonin 2A receptor depends on-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA. 2008;105:1079–84.
• Rodriguiz RM, Nadkarni V, Means CR, Pogorelov VM, Chiu Y-T, Roth BL, et al. LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1. Sci Rep. 2021;11:17690.
• Berno G, Zaccarelli M, Gori C, Tempestilli M, Antinori A, Perno CF, et al. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. BMC Med Genet. 2014;15:1–7.
• Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196–204.
• Schmitz GP, Jain MK, Slocum ST, Roth BL. 5-HT 2A SNPs alter the pharmacological signaling of potentially therapeutic psychedelics. ACS Chem Neurosci. 2022;13:2386–98.
• Davies MA, Setola V, Strachan RT, Sheffler DJ, Salay E, Hufeisen SJ, et al. Pharmacologic analysis of non-synonymous coding h5-HT 2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenom J. 2006;6:42–51.
  CAS Google Scholar
• Bermak JC, Li M, Bullock C, Zhou QY. Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. Nat Cell Biol. 2001;3:492–8.
  PubMed CAS Google Scholar
• Petäjä-Repo UE, Hogue M, Laperrière A, Walker P, Bouvier M. Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor. J Biol Chem. 2000;275:13727–36.
  PubMed Google Scholar
• Jacobsen SE, Ammendrup-Johnsen I, Jansen AM, Gether U, Lindegaard Madsen K, Bräuner-Osborne H. The GPRC6A receptor displays constitutive internalization and sorting to the slow recycling pathway. J Biol Chem. 2017:6910–26.
• Lopez-Gimenez JF, Vilaró MT, Milligan G. Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharm. 2008;74:1278–91.
  CAS Google Scholar
• Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci. 2010;13:622–9.
  PubMed PubMed Central CAS Google Scholar
• Cornea-hé Bert V, Riad M, Singh SK, Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol. 1999;409:187–209.
  Google Scholar
• Cornea-Hébert V, Watkins KC, Roth BL, Kroeze WK, Gaudreau P, Leclerc N, et al. Similar ultrastructural distribution of the 5-HT2A serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat. Neuroscience. 2002;113:23–35.
  PubMed Google Scholar
• Doherty MD, Pickel VM. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 2000;864:176–85.
  PubMed CAS Google Scholar
• Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, et al. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem. 2012;287:44301.
  PubMed PubMed Central CAS Google Scholar
• von Zastrow M, Williams JT. Modulating neuromodulation by receptor membrane traffic in the endocytic pathway. Neuron. 2012;76:22.
  Google Scholar
• Dunn HA, Walther C, Yuan GY, Caetano FA, Godin CM, Ferguson SSG. Role of SAP97 in the regulation of 5-HT2AR endocytosis and signaling. Mol Pharm. 2014;86:275–83.
  Google Scholar
• Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, Roth BL. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem. 2001;276:8269–77.
  PubMed CAS Google Scholar
• Bhattacharyya S, Puri S, Miledi R, Panicker MM. Internalization and recycling of 5-HT 2A receptors activated by serotonin and protein kinase C-mediated mechanisms. PNAS. 2002;29:14470–5.
  Google Scholar
• Raote I, Bhattacharyya S, Panicker MM. Functional selectivity in serotonin receptor 2A (5-HT2A) endocytosis, recycling, and phosphorylation. Mol Pharm. 2013;83:42–50.
  CAS Google Scholar
• Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL, et al. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine 2A receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol Pharm. 2001;60:1020–30.
  CAS Google Scholar
• Toneatti R, Shin JM, Shah UH, Mayer CR, Saunders JM, Fribourg M, et al. Interclass GPCR heteromerization affects localization and trafficking. Sci Signal. 2020;13:3122.
  Google Scholar
• Schmid CL, Streicher JM, Meltzer HY, Bohn LM. Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt. Neuropsychopharmacology. 2014;39:1902–13.
  PubMed PubMed Central CAS Google Scholar
• Martín-Guerrero SM, Alonso P, Iglesias A, Cimadevila M, Brea J, Loza MI, et al. His452Tyr polymorphism in the human 5-HT2A receptor affects clozapine-induced signaling networks revealed by quantitative phosphoproteomics. Biochem Pharm. 2021;185:114440–114440.
  PubMed Google Scholar
• de la Fuente Revenga M, Ibi D, Cuddy T, Toneatti R, Kurita M, Ijaz MK, et al. Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity. Neuropsychopharmacology. 2018;44:443–54. 2. 2018;44
  PubMed PubMed Central Google Scholar
• Moreno JL, Holloway T, Umali A, Rayannavar V, Sealfon SC, González-Maeso J. Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice. Psychopharmacology. 2013;225:217.
  PubMed CAS Google Scholar
• Magalhaes AC, Dunn H, Ferguson SSG. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharm. 2012;165:1717–36.
  CAS Google Scholar
• Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700–6.
  PubMed CAS Google Scholar
• Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 2023;42:112203.
  PubMed PubMed Central CAS Google Scholar
• Farrelly LA, thompson robert, Zhao S, Lepack A, Lyu Y, Bhanu NV, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. https://doi.org/10.1038/s41586-019-1024-7.
• Vázquez-Borsetti P, Cortés R, Artigas F. Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex. 2009;19:1678–86.
  PubMed Google Scholar
• Brog JS, Salyapongse A, Deutch AY, Zahm DS. The patterns of afferent innervation of the core and shell in the “Accumbens” part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol. 1993;338:255–78.
  PubMed CAS Google Scholar
• Mocci G, Jiménez-Sánchez L, Adell A, Cortés R, Artigas F. Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology. 2014;79:49–58.
  PubMed CAS Google Scholar
• Burke DA, Alvarez VA. Serotonin receptors contribute to dopamine depression of lateral inhibition in the nucleus accumbens. Cell Rep. 2022;39:110795.
  PubMed PubMed Central CAS Google Scholar
• Bombardi C. Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex. Front Pharm. 2014;5:68.
  Google Scholar
• Aghajanian GK, Foote WE, Sheard MH. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science (1979). 1968;161:706–8.
  CAS Google Scholar
• Davoudian PA, Shao L-X, Kwan AC. Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem Neurosci. 2023;14:468–80.
  PubMed CAS Google Scholar
• Rijsketic DR, Casey AB, Barbosa DAN, Zhang X, Hietamies TM, Ramirez-Ovalle G, et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacology. 2023;2023. https://doi.org/10.1038/s41386-023-01613-4.
• Yan QS. Activation of 5-HT(2A/2C) receptors within the nucleus accumbens increases local dopaminergic transmission. Brain Res Bull. 2000;51:75–81.
  PubMed CAS Google Scholar
• Maze I, Covingtoni HE, Dietz DM, Laplant Q, Renthal W, Russo SJ, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science. 2010;327:213.
  PubMed PubMed Central CAS Google Scholar
• Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:1–14. 1. 2020;10
  Google Scholar
• Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7:e35082.
  PubMed PubMed Central Google Scholar
• Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;2022. https://doi.org/10.1038/S41591-022-01744-Z.
• Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7:13187. https://doi.org/10.1038/s41598-017-13282-7.
• Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019 Jul;71(3):316-344. https://doi.org/10.1124/pr.118.017160.
• Wagner IC, van Buuren M, Fernández G. Thalamo-cortical coupling during encoding and consolidation is linked to durable memory formation. Neuroimage. 2019;197:80–92.
  PubMed Google Scholar
• Doss MK, Madden MB, Gaddis A, Nebel MB, Griffiths RR, Mathur BN, et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain. 2022;145:441–56.
• Maclean KA, Leoutsakos J-MS, Johnson MW, Griffiths RR. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig. 2012;51:721–37. https://doi.org/10.1111/j.1468-5906.2012.01685.x.
• Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29:1182–90.
• Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. 2017;234:1499.
  PubMed CAS Google Scholar
• Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2011;63:S467–72.
• Rosner RI. Beck Depression Inventory (BDI). The encyclopedia of clinical psychology. 2015:1–6. https://doi.org/10.1002/9781118625392.wbecp261.
• Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res. 2011;63:S454–66.
  Google Scholar
• Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, et al. Psychedelic therapy’s transdiagnostic effects: a research domain criteria (RDoC) perspective. Front Psychiatry. 2021;12:800072.
  PubMed PubMed Central Google Scholar
• Halberstadt AL, Van Der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, et al. 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009;34:1958–67.
  PubMed CAS Google Scholar
• Vohra HZ, Saunders JM, Jaster AM, de la Fuente Revenga M, Jimenez J, Fernández-Teruel A, et al. Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. Psychopharmacology. 2021;2021. https://doi.org/10.1007/S00213-021-05913-9.
• Páleníček T, Hliňák Z, Bubeníková-Valešová V, Novák T, Horáček J. Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:588–96.
  PubMed Google Scholar
• Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice Detection of the behavior based on the dynamics of head movement. https://doi.org/10.1007/s00213-013-3006-z.
• Canal CE, Morgan D. Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal. 2012;4:556–76.
  PubMed PubMed Central CAS Google Scholar
• de la Fuente Revenga M, Vohra HZ, González-Maeso J. Automated quantification of head-twitch response in mice via ear tag reporter coupled with biphasic detection. J Neurosci Methods. 2020;334:108595.
  PubMed PubMed Central Google Scholar
• Jaster AM, Younkin J, Cuddy T, de la Fuente Revenga M, Poklis JL, Dozmorov MG, et al. Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice. Neurosci Lett. 2022;788:136836.
  PubMed PubMed Central CAS Google Scholar
• Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967;11:65–78.
  PubMed CAS Google Scholar
• CORNE SJ, PICKERING RW, WARNER BT. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharm Chemother. 1963;20:106–20.
  CAS Google Scholar
• Keller DL, Umbreit WW. ‘Permanent’ alteration of behavior in mice by chemical and psychological means. Science. 1956;124:723–4.
  PubMed CAS Google Scholar
• Jaster AM, Elder H, Marsh SA, de la Fuente Revenga M, Negus SS, González-Maeso J. Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. Psychopharmacology. 2022;1:1–13.
  Google Scholar
• Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. https://doi.org/10.1073/pnas.2022489118/-/DCSupplemental.
• Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535.
  PubMed PubMed Central CAS Google Scholar
• Willins DL, Meltzer HY. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharm Exp Ther. 1997;282:699–706.
  CAS Google Scholar
• Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: Dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology. 2005;180:427–35.
  PubMed CAS Google Scholar
• Fattore L, Marti M, Mostallino R, Castelli MP. Sex and gender differences in the effects of novel psychoactive substances. Brain Sci. 2020;10:606. VolPage2020;10:606
  PubMed PubMed Central CAS Google Scholar
• Gukasyan N, Narayan SK. Menstrual changes and reversal of amenorrhea induced by classic psychedelics: a case series. 2023:1–6. https://doi.org/10.1080/0279107220222157350.
• Brookshire BR, Jones SR. Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice. Pharm Biochem Behav. 2009;94:194–203.
  CAS Google Scholar
• Korpi ER, den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ, et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse. Pharm Rev. 2015;67:872–1004.
  PubMed CAS Google Scholar
• Mendes FR, Costa CdosS, Wiltenburg VD, Morales-Lima G, Fernandes JAB, Filev R. Classic and non‐classic psychedelics for substance use disorder: a review of their historic, past and current research. Addic Neurosci. 2022;3:100025.
  Google Scholar
• Nichols DE, Grob CS. Is LSD toxic? For Sci Int. 2018;284:141–5.
  CAS Google Scholar
• Haden M, Woods B, Sc M. LSD overdoses: three case reports. J Stud Alcohol Drugs. 2020;81:115–8. vol
  PubMed Google Scholar
• Roberts DM, Premachandra KH, Chan BS, Auld R, Jiranantakan T, Ewers C, et al. A cluster of lysergic acid diethylamide (LSD) poisonings following insufflation of a white powder sold as cocaine. Clin Toxicol. 2021;59:969–74.
  CAS Google Scholar
• Simonsson O, Sexton JD, Hendricks PS. Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol. 2021;35:447–52. Https://DoiOrg/101177/0269881121996863
  PubMed PubMed Central Google Scholar
• Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29:280–8.
  PubMed CAS Google Scholar
• De La Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, González-Maeso J. Tolerance and cross-tolerance among psychedelic and nonpsychedelic 5-HT2A receptor agonists in mice. ACS Chem Neurosci. 2022;13:2436–48.
  PubMed Google Scholar
• Buchborn T, Lyons T, Knöpfel T. Tolerance and tachyphylaxis to head twitches induced by the 5-HT2A agonist 25CN-NBOH in mice. Front Pharm. 2018;9:17.
  Google Scholar
• Grim TW, Acevedo-Canabal A, Bohn LM. Toward directing opioid receptor signaling to refine opioid therapeutics. Biol Psychiatry. 2020;87:15.
  PubMed CAS Google Scholar
• Goodwin AK. An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates. J Pharm Toxicol Methods. 2016;82:31–36.
  CAS Google Scholar
• Simmler LD, Li Y, Hadjas LC, Hiver A, van Zessen R, Lüscher C. Dual action of ketamine confines addiction liability. Nature. 2022;608:368.
  PubMed CAS Google Scholar
• Baker LE. Hallucinogens in drug discrimination. Curr Top Behav Neurosci. 2018;36:201–19.
  PubMed CAS Google Scholar
• McMahon LR. The rise (and fall?) of drug discrimination research. Drug Alcohol Depend. 2015;151:284.
  PubMed PubMed Central Google Scholar
• Stevens Negus S, Miller LL. Intracranial self-stimulation to evaluate abuse potential of drugs. Pharm Rev. 2014;66:869–917.
  PubMed Google Scholar
• Altarifi AA, Rice C, Stevens Negus S. Abuse-related effects of mu opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure. Behav Pharmacol. 2013;24:459-70. https://doi.org/10.1097/FBP.0b013e328364c0bd.
• Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS. Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol. 2019;27:215–26.
  PubMed PubMed Central CAS Google Scholar
• Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11.
  PubMed CAS Google Scholar
• Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481–9.
  PubMed Google Scholar
• Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36:151–8.
  PubMed PubMed Central CAS Google Scholar
• Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48.
  PubMed CAS Google Scholar
• Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399–408.
  PubMed CAS Google Scholar
• Nikolaidis A, Lancelotta R, Gukasyan N, Griffiths RR, Barrett FS, Davis AK. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. J Affect Disord. 2023;324:239–49.
  PubMed Google Scholar
• Gasser P, Holstein D, Yvonne Michel Þ, Rick Doblin þ, Yazar-Klosinski B, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014 Jul;202(7):513-20. https://doi.org/10.1097/NMD.0000000000000113.
• Singleton SP, Wang JB, Mithoefer M, Hanlon C, George MS, Mithoefer A, et al. Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. Front Psychiatry. 2023;13:3012.
  Google Scholar
• Johnson MW, Garcia-Romeu, Roland A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abus. 2017;43:55–60.
  Google Scholar
• Johnson MW. Classic psychedelics in addiction treatment: the case for psilocybin in tobacco smoking cessation. Curr Top Behav Neurosci. 2022;56:213-227. https://doi.org/10.1007/7854_2022_327.
• Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289–99.
  PubMed CAS Google Scholar
• Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. J Am Med Assoc. 2022;2022. https://doi.org/10.1001/jamapsychiatry.2022.2096.
• Schimmel N, Breeksema JJ, Sanne Smith-Apeldoorn Y, Jolien V, van den Brink W, Schoevers RA. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology (Berl). 2022 Jan;239(1):15-33.
• Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155–66.
  PubMed Google Scholar
• Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 2005;29:547–69.
  PubMed CAS Google Scholar
• Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589:474–9.
  PubMed CAS Google Scholar
• Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;2023. https://doi.org/10.1021/ACSCHEMNEURO.2C00718.
• Cameron LP, Benson CJ, Defelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019. 2019;10:3261–70. https://doi.org/10.1021/acschemneuro.8b00692.
• de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.
  PubMed Google Scholar
• Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170.
  PubMed PubMed Central CAS Google Scholar
• Berthoux C, Barre A, Bockaert J, Marin P, Bécamel C. Sustained activation of postsynaptic 5-HT2A receptors gates plasticity at prefrontal cortex synapses. Cereb Cortex. 2019;29:1659–69.
  PubMed Google Scholar
• Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032–41.
  PubMed PubMed Central CAS Google Scholar
• Canal CE, Murnane KS. The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. J Psychopharmacol. 2016;31:127–43. https://doi.org/10.1177/0269881116677104.
  Article PubMed PubMed Central CAS Google Scholar
• Spanagel R. Animal models of addiction. Dialogues Clin Neurosci. 2017;19:247–58.
• McKendrick G, Garrett H, Jones HE, McDevitt DS, Sharma S, et al. Ketamine Blocks Morphine-Induced Conditioned Place Preference and Anxiety-Like Behaviors in Mice. Front Behav Neurosci. 2020;14:75. https://doi.org/10.3389/fnbeh.2020.00075.
• Herzig V, Capuani EMI, Kovar KA, Schmidt WJ. Effects of MPEP on expression of food-, MDMA- or amphetamine-conditioned place preference in rats. Addic Biol. 2005;10:243–9.
  CAS Google Scholar
• Alper K, Cange J, Sah R, Schreiber-Gregory D, Sershen H, Vinod KY. Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. Front Pharm. 2023;13:5314.
  Google Scholar
• Alper K, Dong B, Shah R, Sershen H, Vinod KY. LSD administered as a single dose reduces alcohol consumption in C57BL/6J Mice. Front Pharm. 2018;9:994.
  Google Scholar
• McCool B, Rosenwasser A, Lovinger DM, Alper kennethalper K, Yaragudri Vinod nyumcorg K, Alper K, et al. LSD Administered as a single dose reduces alcohol consumption in C57BL/6J mice. 2018;2018. https://doi.org/10.3389/fphar.2018.00994.
• Oppong-Damoah A, Curry KE, Blough BE, Rice KC, Murnane KS. Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice. Psychopharmacology. 2019;236:3567–78.
  PubMed PubMed Central CAS Google Scholar
• Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharm Transl Sci. 2021;4:568–72.
  CAS Google Scholar
• Jaster AM, de la Fuente Revenga M, González-Maeso J. Molecular targets of psychedelic-induced plasticity. J Neurochem. 2021;2021. https://doi.org/10.1111/JNC.15536.
• Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharm Transl Sci. 2021;4:563–7.
  CAS Google Scholar
• Olson DE. Biochemical mechanisms underlying psychedelic-induced neuroplasticity. Biochemistry. 2022;61:127–36.
• Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25:1407–19.
  PubMed PubMed Central CAS Google Scholar
• Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864–71.
• Qu Y, Chang L, Ma L, Wan X, Hashimoto K. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice. Pharm Biochem Behav. 2023;222:173500.
  CAS Google Scholar
• Murnane KS. Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder. Behav Pharmacol. 2019;30:151–62. https://doi.org/10.1097/FBP.0000000000000459.
• Steinberg LJ, Rubin-Falcone H, Galfalvy HC, Kaufman J, Miller JM, Elizabeth Sublette M, et al. Cortisol stress response and in vivo pet imaging of human brain serotonin 1A receptor binding. Int J Neuropsychopharmacol. 2019;22:329–38.
• Jaggar M, Weisstaub N, Gingrich JA, Vaidya VA. 5-HT2A receptor deficiency alters the metabolic and transcriptional, but not the behavioral, consequences of chronic unpredictable stress. Neurobiol Stress. 2017;7:89–102.
  PubMed PubMed Central Google Scholar
• Saunders JM, Muguruza C, Sierra S, Moreno JL, Callado LF, Meana JJ, et al. Glucocorticoid receptor dysregulation underlies 5-HT2AR-dependent synaptic and behavioral deficits in a mouse neurodevelopmental disorder model. J Biol Chem. 2022;298:102481.
  PubMed PubMed Central CAS Google Scholar
• Levit Kaplan A, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, et al. Bespoke library docking for 5-HT 2A receptor agonists with antidepressant activity. Nature. 2022;610:582–91. https://doi.org/10.1038/s41586-022-05258-z.
• Pacheco AT, Olson RJ, Garza G, Moghaddam B. Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacology. 2023;48:1011–20.
• Odland AU, Kristensen JL, Andreasen JT. Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice. Behav Brain Res. 2021;401:113093.
  PubMed CAS Google Scholar
• Plach M, Schäfer T, Oscar Borroto-Escuela D, Weikert D, Gmeiner P, Fuxe K, et al. Differential allosteric modulation within dopamine D 2 R-neurotensin NTS1R and D 2 R-serotonin 5-HT 2A R receptor complexes gives bias to intracellular calcium signalling. Sci Rep. 2019;9:16312. https://doi.org/10.1038/s41598-019-52540-8.
• Meredith GE. The synaptic framework for chemical signaling in nucleus accumbens. Ann N Y Acad Sci. 1999;877:140–56.
• Russo SJ, Dietz DM, Dumitriu D, Morrison JH, Malenka RC, Nestler EJ. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 2010;33:267–76.
  PubMed PubMed Central CAS Google Scholar
• Pickel VM, Chan J. Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens. J Neurosci. 1999;19:7356–66.
  PubMed PubMed Central CAS Google Scholar
• Zayara AE, McIver G, Valdivia PN, Lominac KD, McCreary AC, Szumlinski KK. Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology. 2011;213:321–35.
  PubMed CAS Google Scholar
• Robinson ES, Dalley JW, Theobald DE, Glennon JC, Pezze MA, Murphy ER, et al. Opposing roles for 5-HT 2A and 5-HT 2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology. 2008;33:2398–406.
  PubMed CAS Google Scholar
• Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, et al. Pharmacologic activity of substituted tryptamines at 5-HT2AR, 5-HT2CR, 5-HT1AR, and SERT. J Pharmacol Exp Ther. 2023:JPET-AR-2022-001454.
• Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal. 2010;22:1406–12.
  PubMed PubMed Central CAS Google Scholar
• Riga MS, Bortolozzi A, Campa L, Artigas F, Celada P. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors. Neuropharmacology. 2016;101:370–8.
  PubMed CAS Google Scholar
• de Montigny C, Aghajanian GK. Preferential action of 5-methoxytryptamine and 5-methoxydimethyltryptamine on presynaptic serotonin receptors: a comparative iontophoretic study with LSD and serotonin. Neuropharmacology. 1977;16:811–8.
  Google Scholar
• McCall RB. Neurophysiological effects of hallucinogens on serotonergic neuronal systems. Neurosci Biobehav Rev. 1982;6:509–14.
  PubMed CAS Google Scholar
• Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328.
  PubMed PubMed Central CAS Google Scholar
• Preller KH, Herdener M, Pokorny T, Liechti ME, Seifritz E, Correspondence FXV. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451–7.
  PubMed CAS Google Scholar
• Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22:621.
  PubMed PubMed Central CAS Google Scholar
• Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7:157–64.
• Nakamura K, Ikoma Y, Kimura K, Nakada Y, Kobayashi S, Yamaguchi M, et al. Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants. Nihon Yakurigaku Zasshi. 1989;94:81–89.
  PubMed CAS Google Scholar
• Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, et al. Pharmacological mechanism of the non-hallucinogenic 5-HT2A agonist ariadne and analogs. ACS Chem Neurosci. 2023;14:119–35.
  PubMed CAS Google Scholar
• Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcult Psychiatry. 2022;59:652–64. https://doi.org/10.1177/1363461520983684.
• Bhatia A, Appelbaum PS, Wisner KL. Unblinding in randomized controlled trials: a research ethics case. Ethics Hum Res. 2021;43:28–34.
  PubMed PubMed Central Google Scholar
• Cameron LP. Citizen science asking questions of psychedelic microdosing. Elife. 2021;10:e66920.
  PubMed PubMed Central Google Scholar
• Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239:1989–2010.
  PubMed PubMed Central CAS Google Scholar
• Butler M, Jelen L, Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology. 2022;239:3047–55.
  PubMed PubMed Central CAS Google Scholar
• von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809.
• Cavanna F, Muller S, de la Fuente LA, Zamberlan F, Palmucci M, Janeckova L, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12:1–11.
  Google Scholar
• Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology. 2019;236:1159–70.
  PubMed CAS Google Scholar
• Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology. 2018;235:521–34.
  PubMed CAS Google Scholar
• Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Int J Neuropsychopharmacol. 2022;2022. https://doi.org/10.1093/IJNP/PYAC075.
• Gukasyan N. On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Med. 2023;4:8–9.
  PubMed CAS Google Scholar
• Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022;36:1100–17.
  PubMed PubMed Central Google Scholar